Linear regression models of FEV1% predicted among white patients
| Number of patients in model | Adjusted USA–UK effect (95% CI) | |
|---|---|---|
| Model 1: adjusted for age at encounter | N=22 867 | 3.31 (2.65 to 3.96) |
| Model 2: adjusted for age at encounter, gender, age at diagnosis, pancreatic sufficiency and genotype | N=22 591 | 3.03 (2.37 to 3.69) |
| Model 3: adjusted for age at encounter, gender, age at diagnosis, pancreatic sufficiency, genotype, chronic Pseudomonas infection, chronic MSSA infection, Burkholderia cepacia infection and MRSA infection | N=22 276 | 3.85 (3.17 to 4.53) |
| Model 3 stratified by age group | ||
| <12 years | N=4681 | 7.62 (6.24 to 9.00) |
| 12–17 years | N=5078 | 6.65 (5.21 to 8.08) |
| 18–23 years | N=4578 | 5.20 (3.64 to 6.75) |
| 24 years + | N=7939 | 0.26 (−0.88 to 1.39) |
Results are presented as difference between the USA–UK of FEV1% predicted (95% CI).
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.